Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;99(11):e231-4.
doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4.

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

Julio Delgado  1 , Itziar Salaverria  2 , Tycho Baumann  3 , Alejandra Martínez-Trillos  2 , Eriong Lee  2 , Laura Jiménez  2 , Alba Navarro  2 , Cristina Royo  2 , Rodrigo Santacruz  3 , Cristina López  2 , Angel R Payer  4 , Enrique Colado  4 , Marcos González  5 , Lluís Armengol  6 , Dolors Colomer  2 , Magda Pinyol  2 , Neus Villamor  2 , Marta Aymerich  2 , Ana Carrió  2 , Dolors Costa  2 , Guillem Clot  2 , Eva Giné  3 , Armando López-Guillermo  3 , Elías Campo  2 , Sílvia Beà  2
Affiliations

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

Julio Delgado et al. Haematologica. 2014 Nov.
No abstract available

Keywords: 17p deletion; CLL; CN-arrays; IGHV; TP53; genome complexity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Graphical representation of the whole cohort of patients according to TP53 alterations. The percentage of cells with 17p deletion by FISH is illustrated in the vertical bar plots. The squares below indicate the presence of 17p losses by copy number arrays (red: loss; green: copy number neutral loss of heterozygosity; gray: wild type; white: not available); copy number alterations; 17p deletions by chromosome banding analysis (red: presence; gray: absence; white: not available); complex karyotype by chromosome banding analysis (red: presence; gray: absence; white: not available); TP53 mutations by sequencing (red: presence; gray: absence; white: not available); NOTCH1 mutations by sequencing (red: presence; gray: absence; white: not available); SF3B1 mutations by sequencing (red: presence; gray: absence; white: not available); IGHV mutational status by sequencing (red: unmutated; gray: mutated; white: not available); CD38 expression (red: high; gray: low; white: not available); ZAP70 expression (red: high; gray: low; white: not available); type of TP53 disruption (red: de novo; gray: acquired).
Figure 2.
Figure 2.
Copy number profiles of cases with de novo (A) and acquired (B) TP53 disruption. In the x-axis the chromosomes are represented horizontally from 1 to 22, in the y-axis the percentage of cases showing the copy number alterations. Gains are represented in the positive y-axis and colored in blue, whereas losses are represented in the negative y-axis in red.
Figure 3.
Figure 3.
(A) Time to first treatment in patients with de novo TP53 disruption according to IGHV mutational status [(mutated (n = 6) vs. unmutated (n = 20)]; (B) overall survival in patients with TP53 disruption according to the number of copy number alterations [0–3 (n=18) vs.4–9 (n=15) vs. more than 9 (n=8)].
See this image and copyright information in PMC

References

    1. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Eng J Med. 1990;323(11):720–4. - PubMed
    1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6. - PubMed
    1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370(9583):230–9. - PubMed
    1. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O’Brien S, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114(5):957–64. - PMC - PubMed
    1. Delgado J, Espinet B, Oliveira AC, Abrisqueta P, de la Serna J, Collado R, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol. 2012;157(1):67–74. - PubMed

Publication types

MeSH terms

Substances